Uveites as paradoxal reaction or nonefficacy of treatment in ankylosing spondylitis patients, getting inhibitors of alpha tumour necrosis factor
- Authors: Gaidukova I.Z.1,2, Samigulina R.R.1, Vasilenko E.A.1, Inamova O.V.2, Gaidukova E.K.3, Trophimov E.A.1, Mazurov V.I.1
-
Affiliations:
- Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation
- State Budgetary healthcare institution "Clinical hospital of rheumatology 25" of the Ministry of Healthcare of the Russian Fedeatio
- Federal state autonomous educational institution of higher Education "St. Petersburg national research university of informational technologies, mechaniks and optics"
- Issue: No 4 (2018)
- Pages: 43-50
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/279389
- ID: 279389
Cite item
Open Access
Access granted
Abstract
Aim of the research. Analysis of the occurrence and features of newly emerged and previously available uveites in patients with ankylosing spondylitis (AS), receiving tumor necrosis factor а (FNOα) inhibitors. Material and methods. 119 AS patients older 18 years, matching New York AS criteria, taking therapy by FNOα inhibitors not less than 5 years were included in the study. Middle time period of patients' observation was 7,1 ±1,3 years. Results. More than in 80% of patients, having uveites before the start of genetically engineered biologic therapy, had no more recurrence of uveitis on the phone of FNOα intake. It is fixed the association between the efficacy of musculosceletal pathology treatment in case of AS and reduce of uveitis recurrence risk in case of their presence before the start of the therapy, but it is not fixed the association of treatment efficacy with reduce of uveites de novo arising risk. Uveites de novo arising risk in case of FNOα inhibitors use is comparatible with the risk of uveites recurrence in patients with uveites in their anamnesis. Adalilumab and golimumab use is associated with less risk of uveites de novo development, than infliximab and etanercept use. Recurrences of uveites in patients with uveites in anamnesis are developing more often during the first year of FNOα inhibitors therapy; arising of de novo uveites - after 2-6 years from the beginning of these medicines use. Uveites de novo, caused by the use of monoclonal antibodies to FNOα, are in most cases acute, well-stopped by local medicaments and do not require the replacement of genetically engineered biological remedies. Conclusions. For development of adequate measures for the treatment and prevention of recurrence and new episodes of uveites on the pnone of FNOα inhibitors therapy in case of AS, additional studies are needed to study the features of the pathogenesis of uveitis as a paradoxical reaction to treatment or a sign of ineffective AS treatment.
Full Text
About the authors
Inna Z. Gaidukova
Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation; State Budgetary healthcare institution "Clinical hospital of rheumatology 25" of the Ministry of Healthcare of the Russian Fedeatio
Email: ubp1976@list.ru
MD, associate professor of the Department of therapy and rheumatology named after Ae.Ae. Aeikhvald
Ruzana R. Samigulina
Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation
Email: Ruzana.Samigulina@szgmu.ru
rheumatologist, chief of GBIT center
Elizaveta A. Vasilenko
Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation
Email: elisaavas@gmail.com
PhD candidate of the Department of therapy and rheumatology named after Ae.Ae. Aeikhvald
Oksana V. Inamova
State Budgetary healthcare institution "Clinical hospital of rheumatology 25" of the Ministry of Healthcare of the Russian Fedeatio
Email: b25@zdrav.spb.ru
PhD, chief doctor of State Budgetary Healthcare Institution CRH 25.
Ekaterina K. Gaidukova
Federal state autonomous educational institution of higher Education "St. Petersburg national research university of informational technologies, mechaniks and optics"
Email: kgaydukova97@mail.ru
3rd course student
Evgeny A. Trophimov
Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation
Email: Evgeniy.trofimov@szgmu.ru
PhD, assistant professor of the Department of therapy and rheumatology named after Ae.Ae. Aeikhvald
Vadim I. Mazurov
Federal state budgetary institution of higher education "I.I. Mechnikov North-Western state medical university" of the Ministry of Healthcare of the Russian Fedeation
Email: maz.nwgmu@yandex.ru
MD, academician of RAS, head of the Department of therapy and rheumatology named after Ae.Ae. Aeikhvald
References
- Jani M., Dixon W.G., Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford). 2018: 8. doi: 10.1093/rheumatology/kex434. [Epub ahead of print].
- Peer F.C., Miller A., Pavli P., Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.Intern Med J. 2017; 47(12): 1445-1448. doi: 10.1111/imj.13637.
- Puig L. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. Curr Probl Dermatol. 2018; 53: 49-63. doi: 10.1159/000479475. Epub 2017 Nov 7.
- Kolios A.G.A., Biedermann L., Weber A., Navarini A.A., Meier J., Cozzio A., French L.E. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.Br J Dermatol. 2018; 178(2): 551-555. doi: 10.1111/bjd.15631. Epub 2017 Nov 28.
- Ciccarelli F., De Martinis M., Sirufo M.M., Ginaldi L. Psoriasis Induced by Anti-Tumor NecrosisFactor Alpha Agents: A Comprehensive Review of the Literature. Acta Dermatovenerol Croat. 2016; 24(3): 169-74. Review.
- Sampaio-Barros P.D., van der Horst-Bruinsma I.E. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol. 2014; 28(5): 747-63. doi: 10.1016/j.berh.2014.10.001.
- Yu S., Mao C., Yu J., Qi X., Wang J., Lu H. A study of the key genes and inflammatory signaling pathways involved in HLA-B27-associated acute anterior uveitis families. Int J Mol Med. 2018; 42(1): 259-269. doi: 10.3892/ijmm.2018.3596.
- Killian M., Touraine R., Amouzougan A., Thomas T., Marotte H. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis. Ann Rheum Dis. 2015; 74(3): e22. doi: 10.1136/annrheumdis-2014-206776. Epub 2014 Dec 2.
- van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4): 361-8.
- Гайдукова И.З., Ребров А.П., Коротаева Т.В., Дубинина Т.В., Оттева Э.Н., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.И., Иванова О.Н., Лапшина С.А., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.Ф. Ремиссия при аксиальных спондилоартритах - определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научно-практическая ревматология. 2018; 56(1): 10-14. https://doi.org/10.14412/1995-4484-2018-10-14.
- Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52(8): 2447-51.
- Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56(10): 3248-52.
- Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010; 9(3): 188-93. doi: 10.1016/j. autrev.2009.10.003. Epub 2009 Oct 23.
- Lie E., Lindström U., Zverkova-Sandström T., Olsen I.C., Forsblad-d'Elia H., Askling J., Kapetanovic M.C., Kristensen L.E., Jacobsson LTH. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017; 76(9): 1 515-1 521. doi: 10.1136/annrheumdis-2016-210931. Epub 2017 Mar 2.
- Fabiani C., Vitale A., Lopalco G., Iannone F., Frediani B., Cantarini L. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol.2016 Nov; 35(11): 2631-2638. Epub 2016 Sep 30.
- López-Hernández R., Valdés M., Campillo J.A., Martínez-Garcia P., Salama H., Salgado G., Boix F., Moya-Quiles M.R., Minguela A., Sánchez-Torres A., Miras M., Garcia A., Carballo F., Âlvarez-López M.R., Muro M. Genetic polymorphisms of tumour necrosis factor alpha (TNF-a) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet. 2014; 41(1): 63-8. doi: 10.1111/iji.12059. Epub 2013 Apr 17.
- Liu J., Dong Z., Zhu Q., He D., Ma Y., Du A., He F., Zhao D., Xu X., Zhang H., Jin L., Wang J. TNF-a Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis. Sci Rep. 2016; 6: 32202. doi: 10.1038/srep32202.
- Varkas G., Vastesaeger N., Cypers H., Colman R., Renson T., Van Praet L., Carron P., Raeman F., Devinck M., Gyselbrecht L., Corluy L., Piette Y., Lenaerts J., Thevissen K., Vanneuville B., Van den Bosch F., Elewaut D. Inflammatory bowel disease and acute anterior uveitis, but not psoriasis are associated with disease duration in Axial SpA: results from the (Be)Giant and ASPECT cohort. Arthritis Rheumatol. 2018. doi: 10.1002/art.40551.
- Kim M., Sim Y.S., Choi S.Y., Park Y.H. Potential predictors for frequent relapse in human leukocyte antigen-B27-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2018. doi: 10.1007/s00417-018-4002-0.
Supplementary files
